BR112014013495A2 - antibodies to epidermal growth factor receptor 3 (her3) targeting her3 domain iii and domain iv - Google Patents

antibodies to epidermal growth factor receptor 3 (her3) targeting her3 domain iii and domain iv

Info

Publication number
BR112014013495A2
BR112014013495A2 BR112014013495A BR112014013495A BR112014013495A2 BR 112014013495 A2 BR112014013495 A2 BR 112014013495A2 BR 112014013495 A BR112014013495 A BR 112014013495A BR 112014013495 A BR112014013495 A BR 112014013495A BR 112014013495 A2 BR112014013495 A2 BR 112014013495A2
Authority
BR
Brazil
Prior art keywords
her3
antibodies
domain
ligand
fragments
Prior art date
Application number
BR112014013495A
Other languages
Portuguese (pt)
Other versions
BR112014013495A8 (en
Inventor
Paul Garner Andrew
Carsten Silvester Kunz Christian
Anne Reisinger Sprague Elizabeth
Huet Heather
Haubst Nicole
Sheng Qing
Ettenberg Seth
Elis Winfried
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112014013495A8 publication Critical patent/BR112014013495A8/en
Publication of BR112014013495A2 publication Critical patent/BR112014013495A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

abstract the present invention relates to antibodies or fragments thereof that bind to a non-linear epitope within domain 3 of the her3 receptor and inhibit both ligand-dependent and ligand-independent signal transduction. the invention also relates antibodies or fragments thereof that bind to amino acid residues within domains 3-4 of her3 and inhibit both ligand-dependent and ligand-independent signal transduction; and compositions and methods of use of such antibodies or fragments thereof. tradução do resumo resumo patente de invenção: "anticorpos para o receptor 3 do fator de crescimento epidérmico (her3) direcionados para o domínio iii e domíniuo iv de her3". a presente invenção refere-se a anticorpos ou seus fragmentos que se ligam a um epítopo não linear dentro do domínio 3 do receptor de her3 e inibem a transdução do sinal dependente do ligante e independente do ligante. a invenção também se refere a anticorpos ou seus fragmentos que se ligam aos resíduos de aminoácidos dentro dos domínios 3-4 de her3 e inibem a transdução do sinal dependente do ligante e independente do ligante; e composições e métodos de uso de tais anticorpos ou seus fragmentos.abstract the present invention relates to antibodies or fragments thereof that bind to a nonlinear epitope within domain 3 of the her3 receptor and inhibit both ligand-dependent and ligand-independent signal transduction. the invention also relates antibodies or fragments thereof that bind to amino acid residues within domains 3-4 of her3 and inhibit both ligand-dependent and ligand-independent signal transduction; and compositions and methods of use of such antibodies or fragments thereof. "antibodies to epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3". The present invention relates to antibodies or fragments thereof that bind to a nonlinear epitope within the her3 receptor domain 3 and inhibit ligand-dependent and ligand-independent signal transduction. The invention also relates to antibodies or fragments thereof that bind to amino acid residues within her3 domains 3-4 and inhibit ligand-dependent and ligand-independent signal transduction; and compositions and methods of using such antibodies or fragments thereof.

BR112014013495A 2011-12-05 2012-12-04 antibodies to epidermal growth factor receptor 3 (her3) targeting her3 domain iii and domain iv BR112014013495A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161566912P 2011-12-05 2011-12-05
PCT/IB2012/056956 WO2013084151A2 (en) 2011-12-05 2012-12-04 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3

Publications (2)

Publication Number Publication Date
BR112014013495A8 BR112014013495A8 (en) 2017-06-13
BR112014013495A2 true BR112014013495A2 (en) 2017-06-13

Family

ID=47561692

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014013495A BR112014013495A2 (en) 2011-12-05 2012-12-04 antibodies to epidermal growth factor receptor 3 (her3) targeting her3 domain iii and domain iv

Country Status (16)

Country Link
EP (1) EP2788381A2 (en)
JP (1) JP2015500830A (en)
KR (1) KR20140099315A (en)
CN (1) CN104093742A (en)
AR (1) AR089085A1 (en)
AU (1) AU2012349739A1 (en)
BR (1) BR112014013495A2 (en)
CA (1) CA2857939A1 (en)
EA (1) EA201491120A1 (en)
IL (1) IL232950A0 (en)
IN (1) IN2014CN04374A (en)
MX (1) MX2014006731A (en)
SG (1) SG11201402784WA (en)
TW (1) TW201331225A (en)
UY (1) UY34488A (en)
WO (1) WO2013084151A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3110849T1 (en) * 2014-02-28 2021-01-29 Merus N.V. Antibody that binds erbb-2 and erbb-3
AU2015223566B2 (en) 2014-02-28 2020-10-08 Merus N.V. Antibodies that bind EGFR and ErbB3
EP3539990B1 (en) 2014-07-16 2021-09-08 Dana-Farber Cancer Institute, Inc. Her3 inhibition in low-grade serous cancers
CN104530237B (en) * 2014-12-31 2017-09-05 百泰生物药业有限公司 Anti- Her1 therapeutic antibodies
SI3365373T1 (en) 2015-10-23 2021-08-31 Merus N.V. Binding molecules that inhibit cancer growth
JP6729926B2 (en) * 2016-05-12 2020-07-29 国立大学法人神戸大学 ErbB3 activation signal transduction inhibitor and method for screening the same
MX2019002664A (en) * 2016-09-15 2019-09-26 Univ Stuttgart Antigen binding protein against her3.
KR101923641B1 (en) * 2016-11-25 2018-11-29 재단법인 목암생명과학연구소 Anti-HER3 antibody and composition for preventing or treating cancer comprising the same
WO2018182422A1 (en) 2017-03-31 2018-10-04 Merus N.V. Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR056857A1 (en) * 2005-12-30 2007-10-24 U3 Pharma Ag DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES
US8362215B2 (en) * 2009-04-29 2013-01-29 Trellis Bioscience, Llc Antibodies immunoreactive with heregulin-coupled HER3
NO2719708T3 (en) * 2009-11-13 2018-03-24
KR101764453B1 (en) * 2010-04-09 2017-08-02 아베오 파마슈티컬즈, 인크. Anti-erbb3 antibodies
TW201302793A (en) * 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding proteins
NO2707391T3 (en) * 2011-05-13 2018-04-07
CA2842860A1 (en) * 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Sur-binding proteins

Also Published As

Publication number Publication date
AR089085A1 (en) 2014-07-30
SG11201402784WA (en) 2014-06-27
EA201491120A1 (en) 2015-07-30
AU2012349739A1 (en) 2014-06-26
IN2014CN04374A (en) 2015-09-04
EP2788381A2 (en) 2014-10-15
UY34488A (en) 2013-07-31
MX2014006731A (en) 2015-06-04
CA2857939A1 (en) 2013-06-13
JP2015500830A (en) 2015-01-08
IL232950A0 (en) 2014-07-31
CN104093742A (en) 2014-10-08
TW201331225A (en) 2013-08-01
WO2013084151A2 (en) 2013-06-13
KR20140099315A (en) 2014-08-11
BR112014013495A8 (en) 2017-06-13
WO2013084151A3 (en) 2014-01-03

Similar Documents

Publication Publication Date Title
BR112014013495A8 (en) antibodies to epidermal growth factor receptor 3 (her3) targeting her3 domain iii and domain iv
BR112014013568A8 (en) epidermal growth factor 3 (her3) receptor antibodies directed to her3 domain ii
CY1123145T1 (en) ANTI-CD40 ANTIBODIES
CL2012003093A1 (en) Multivalent isolated antibody that has at least two receptor binding domains for two different binding sites of a lrp6 target receptor that inhibit a canonical wnt signal transduction pathway; biparatopic isolated antibody that binds lrp6; nucleic acid encoding it; vector comprising said nucleic acid; pharmaceutical composition comprising a multivalent anti-lrp6 antibody; method of obtaining said antibody; and its use to treat cancer.
JO3118B1 (en) Compositions and methods for antibodies targeting complement protein c5
BR112014006390A2 (en) antibodies, variable domains and chains made especially for human use
BR112013004012A2 (en) antibodies to epidermal growth factor receptor 3 (her3).
WO2011119979A3 (en) Antibodies to muc16 and methods of use thereof
MX353706B (en) Antibodies binding preferentially human csf1r extracellular domain 4 and their use.
BR112014015111A2 (en) p-factor targeting antibody compositions and processes
BR112012008385A2 (en) p13 kinase inhibitors and their use.
BR112015006060A2 (en) kir3dl2 binding agents
BR112014011351A2 (en) acc inhibitors and uses thereof
BR112013020500A2 (en) isolated, recombinant or purified antibody
NZ604510A (en) Dilutable biocidal compositions and methods of use
BR112012017051A2 (en) method to decrease immunogenicity
BR112012010266A2 (en) anti-fractalquinine antibody or fkn-binding fragment thereof, pharmaceutical composition, nucleic acid, vector, host cell, methods for preparing an anti-fractalquinine antibody or fkn-binding fragment thereof, and for treating an inflammatory disorder, and, use of an antibody or fkn binding fragment thereof
BR112012016309A2 (en) "portion, pharmaceutical composition, use of an effective amount of the portion, method for identifying an ig-like portion that binds to a vascular endothelial growth factor receptor (vegf receptor); and, isolated antibody or a portion antigen binding agent ".
WO2010042636A3 (en) Telomerase inhibitors and methods of use thereof
BR112013031943A2 (en) "g-csfr proteins and antibodies, composition comprising them and use thereof".
MX2013002960A (en) Antibody compositions and methods of use.
MX2017009680A (en) Single domain antibodies targeting cd1d.
BR112013000840A2 (en) method for enhancing the effect of potentiated activated form of antibody to biological endogenous molecule, pharmaceutical composition and use of combination of endogenous biological molecule with potentiated activated form of antibody to endothelial synthase.
ATE539152T1 (en) NEW PROCEDURES
UY34231A (en) DISPOSAL OF INHIBITORS FROM THE MICROBIAL FERMENTATION OF CELLULOSIZED HYDROLYZES OR OTHER COMPOSITIONS CONTAINING INHIBITORS

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]